Skip to content

Viridian Therapeutics, Inc.

VRDN· NasdaqCore metricsCIK 1590750

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -2.43%
Market cap
$3.46B
113.56M shares
Filings
821
$25.75M
Q3 2026+23,359.9% FY25 yoy
-$101.21M
Q3 2026N/M FY25 yoy
-$103.48M
Q3 2026N/M FY25 yoy
-$319.45M
Q3 2026derivedN/M FY25 yoy
-$1.15
Q3 2024N/M FY23 yoy
$172.86M
Q3 2026+113.2% FY25 yoy
$3.46B
—
131.6×
6.0×
-9.92%
—

Twelve months to Sep 30, 2026 · derived

Price

$30.48+7.29%+$2.07past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$70.85MFY 2025
$70.85M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$70,849,000reported
FY 20242024-12-31$302,000reported
FY 20232023-12-31$314,000reported
FY 20222022-12-31$1,772,000reported
FY 20212021-12-31$2,963,000reported
FY 20202020-12-31$1,050,000reported
FY 20192019-12-31$4,461,000reported
FY 20182018-12-31$8,386,000reported
FY 20172017-12-31$4,003,000reported
FY 20162016-12-31$3,477,000 revisedreported
FY 20152015-12-31$5,706,000 revisedreported
FY 20142014-12-31$6,484,000reported

Capital returns

Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2016—$2.00K$2.00K—21.37M sh+99.6%—

Segments

Products
Revenue by Products, FY2019 to FY2025FY2019Collaboration revenue · FY2019 · $4.31MGrant revenue · FY2019 · $153.00KReimbursement Revenue · FY2019 · $4.31MFY2020Collaboration Revenue · FY2020 · $735.00KCollaboration revenue · FY2020 · $735.00KGrant revenue · FY2020 · $315.00KReimbursement Revenue · FY2020 · $681.00KFY2021Collaboration Revenue · FY2021 · $2.96MFY2023Collaboration · FY2023 · $314.00KFY2024Collaboration · FY2024 · $302.00KFY2025License · FY2025 · $70.00MCollaboration · FY2025 · $849.00K
LineFY2025ShareChange
License$70.00M99%—
Collaboration$849.00K1.2%+181.1%
Collaboration Revenue———
Collaboration revenue———
Grant revenue———
Reimbursement Revenue———
Total$70.85M

From the 10-K filed Feb 26, 2026VRDN

Pharmaceutical preparations

Viridian Therapeutics, Inc. is the 115th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR